Technologies

Genzyme has been a global leader in the development of protein therapeutics since our initial enzyme replacement therapy, Ceredase^® (alglucerase injection), was approved for Type I Gaucher disease, a lysosomal storage disease (LSD), in 1991. Our continuing commitment to treating the LSDs has resulted in the approval of other enzyme replacement therapies: Cerezyme^® (imiglucerase for injection), a second generation enzyme therapy for Gaucher disease; Aldurazyme^® (laronidase) for Mucopolysaccharidosis I (in partnership with BioMarin); Fabrazyme^® (agalsidase beta) for Fabry disease; and Myozyme^® (alglucosidase alfa) in late stage clinical development for Pompe disease.

Antibody therapeutics are also playing an increasingly important role in the treatment of human disease. Genzyme’s Campath^® (alemtuzumab) is a humanized monoclonal antibody for the treatment of B-cell chronic lymphocytic leukemia. GC1008, also a fully human monoclonal antibody, is in clinical development in collaboration with Cambridge Antibody Technology and has potential for treating a variety of diseases. Thymoglobulin^® (anti-thymocyte globulin, rabbit) is an immunosuppressive polyclonal antibody that is used in conjunction with concomitant immunosuppression to treat acute rejection in transplant patients.

Genzyme has additional products and development programs that use a diversity of protein product platforms - enzyme, hormone, monoclonal antibody, polyclonal antibody, soluble receptor and peptide. Each protein is unique and requires extensive research, sophisticated knowledge and meticulous execution of complex techniques in genetics, molecular biology, biochemistry, and cell culture in order to transform the protein into a product that could improve patients’ lives.
Protein Therapies publications more >.

Learn more about the process of manufacturing our protein therapy based products through video and animation

Genzyme is a world leader in the field of polymer therapeutics. Our scientists have devised novel polymer-based drugs capable of binding and eliminating unwanted substances in the gastro-intestinal tract. This therapeutic technology has generated two non-absorbed products: Renagel^® (sevelamer hydrochloride) for phosphate control and Welchol^® (colesevelam hydrochloride) for lipid lowering. Polymer Therapeutics publications more >.

Drug discovery and development at Genzyme is focused on finding and delivering to patients, life-saving small molecule therapeutics for diseases with serious unmet needs including cancer, genetic disease, renal disease, and neurodegenerative diseases. In addition to Clolar^® (clofarabine) for intravenous infusion, an approved purine nucleoside anti-metabolite for pediatric acute lymphoblastic leukemia, Genzyme is conducting several clinical studies of small molecules, including Genz-112638 for lysosomal storage disorders; deferitrin for the treatment of transfusional iron overload; and two programs in oncology. Genzyme also has an extensive and diverse pre-clinical small molecule program, which is facilitated by an extensive proprietary library of compounds, expertise in automated synthesis, medicinal chemistry, high-throughput screening, and biochemical target validation.
Small Molecule Therapeutics publications more >.

Genzyme's leadership in surgical biomaterials traces its roots to the company's early years. Since 1984, Genzyme has been a leader in the high-quality production of sodium hyaluronate, or HA, a naturally occurring biopolymer that has many medical indications. Over the years, Genzyme has pioneered the development and commercialization of HA-based medical products, and brings a suite of HA-based products to the market, including Synvisc^® (hylan G-F 20) for the pain associated with osteoarthritis of the knee, and the Sepra^TM family of products designed to prevent or reduce adhesions and other adverse consequences of surgery. Genzyme is increasingly focused on combining biomaterials with local delivery of therapeutics including cells, and proteins.
Biomaterials publications more >.

Genzyme first began gene therapy research in 1991. Since then, our efforts have expanded to include research and development programs in cardiovascular, neurometabolic, and genetic diseases using a wide variety of gene delivery platforms.
Gene Therapy publications more >.

Back to Top

Terms and Conditions of Use | Privacy Policy | © 2002-2012 Genzyme Corporation, a Sanofi company. All rights reserved.